Hypercoagulable States

被引：78

作者：

Anderson, Julia A. M. ^{[2
,3
,4
]}

Weitz, Jeffrey I. ^{[1
,5
]}

机构：

[1] McMaster Univ, Dept Med, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON L8L 2X2, Canada

[2] Royal Infirm Edinburgh NHS Trust, Dept Clin, Edinburgh EH16 4SA, Midlothian, Scotland

[3] Royal Infirm Edinburgh NHS Trust, Hematol Lab, Edinburgh EH16 4SA, Midlothian, Scotland

[4] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada

[5] McMaster Univ, Dept Biochem & Biomed Sci, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON L8L 2X2, Canada

来源：

CRITICAL CARE CLINICS | 2011年 / 27卷 / 04期

关键词：

Thrombophilia; Hypercoagulable state; Thrombosis; Thromboprophylaxis; Anticoagulation; ACTIVATED PROTEIN-C; HEPARIN-INDUCED THROMBOCYTOPENIA; ORAL ANTICOAGULANT-THERAPY; MOLECULAR-WEIGHT HEPARIN; FACTOR-V MUTATIONS; VENOUS THROMBOEMBOLISM; RISK-FACTORS; S DEFICIENCY; METHYLENETETRAHYDROFOLATE REDUCTASE; ANTIPHOSPHOLIPID ANTIBODIES;

D O I：

10.1016/j.ccc.2011.09.007

中图分类号：

R4 [临床医学];

学科分类号：

100218 [急诊医学];

摘要：

Hypercoagulable states can be inherited or acquired. Inherited hypercoagulable states can be caused by a loss of function of natural anticoagulant pathways or a gain of function in procoagulant pathways. Acquired hypercoagulable risk factors include a prior history of thrombosis, obesity, pregnancy, cancer and its treatment, antiphospholipid antibody syndrome, heparin-induced thrombocytopenia, and myeloproliferative disorders. Inherited hypercoagulable states combine with acquired risk factors to establish the intrinsic risk of venous thromboembolism for each individual. Venous thromboembolism occurs when the risk exceeds a critical threshold. Often a triggering factor, such as surgery, pregnancy, or estrogen therapy, is required to increase the risk above this critical threshold.

引用

页码：933 / +

页数：21

共 118 条

[1]

Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. [J].

Agnelli, G ;

Prandoni, P ;

Santamaria, MG ;

Bagatella, P ;

Iorio, A ;

Bazzan, M ;

Moia, M ;

Guazzaloca, G ;

Bertoldi, A ;

Tomasi, C ;

Scannapieco, G ;

Ageno, W ;

Ascani, A ;

Villalta, S ;

Frulla, M ;

Mosena, L ;

Girolami, A ;

Vaccarino, A ;

Alatri, A ;

Palareti, G ;

Marchesi, M ;

Ambrosio, GB ;

Parisi, R ;

Doria, S ;

Steidl, L ;

Ambrosini, F ;

Silingardi, M ;

Ghirarduzzi, A ;

Iori, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :165-169

[2]

Aiach M, 2006, HEMOSTASIS THROMBOSI, P779

[3]

PROTEIN-C INFUSION IN A PATIENT WITH INHERITED PROTEIN-C DEFICIENCY CAUSED BY 2 MISSENSE MUTATIONS - ARG 178 TO GLN AND ARG-1 TO HIS [J].

ALHENCGELAS, M ;

EMMERICH, J ;

GANDRILLE, S ;

AUBRY, ML ;

BENAILY, N ;

FIESSINGER, JN ;

AIACH, M .

BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (01) :35-41

[4]

AMBRUSO DR, 1982, BLOOD, V60, P78

[5]

Use of antithrombotic agents during pregnancy [J].

Bates, SA ;

Greer, IA ;

Hirsh, J ;

Ginsberg, JS .

CHEST, 2004, 126 (03) :627S-644S

[6]

Bauer K.A., 2005, Hematology: Basic Principles and Practice, P2197

[7]

MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].

BERTINA, RM ;

KOELEMAN, BPC ;

KOSTER, T ;

ROSENDAAL, FR ;

DIRVEN, RJ ;

DERONDE, H ;

VANDERVELDEN, PA ;

REITSMA, PH .

NATURE, 1994, 369 (6475) :64-67

[8]

CHEMOTHERAPY ENHANCES ENDOTHELIAL-CELL REACTIVITY TO PLATELETS [J].

BERTOMEU, MC ;

GALLO, S ;

LAURI, D ;

LEVINE, MN ;

ORR, FW ;

BUCHANAN, MR .

CLINICAL & EXPERIMENTAL METASTASIS, 1990, 8 (06) :511-518

[9]

Brandt JT, 1995, THROMB HAEMOSTASIS, V74, P1597

[10]

Brattström L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894

← 1 2 3 4 5 6 7 8 9 10 →